Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
复制标题
DOI：
10.1016/j.mehy.2020.109765
复制
发表时间：
2020-07-01
影响因子：
4.7
通讯作者：
Pindiprolu, Sai Harshini
中科院分区：
文献类型：
--
作者：
Pindiprolu, Sai Kiran S. S.;Pindiprolu, Sai Harshini
截至 2020 年 3 月 25 日，2019 年冠状病毒病 (COVID-19) 大流行已导致全球 18 440 人死亡，对公共健康构成严重威胁。因此，需要有效的治疗策略来治愈这种疾病。然而，高损耗率、高昂的成本和缓慢的步伐是新药发现的主要限制。通过使用“旧”药物治疗“新”疾病来重新利用药物是药物发现中一种有吸引力的方法。氯硝柳胺 (NIC) 是一种经批准的抗蠕虫药物，具有多种抗病毒机制。在这项工作中，我们假设 NIC 针对 COVID-19 的潜在抗病毒机制。
Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.